AstraZeneca plans to list on NYSE, but will remain in the U.K.

Core Viewpoint - AstraZeneca plans to switch to a direct listing of its shares in the United States to capitalize on the booming U.S. stock market [1] Group 1: Company Strategy - The company aims to maximize gains from the U.S. stock market through this direct listing approach [1]